如何开发艰难梭状芽孢杆菌控制性人体感染模型。

IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Clinical Microbiology and Infection Pub Date : 2024-08-29 DOI:10.1016/j.cmi.2024.08.025
Annefleur D O Hensen, Maria J G T Vehreschild, Dale N Gerding, Oleg Krut, Wilbur Chen, Vincent B Young, Saul Tzipori, Philipp Solbach, Malick Mahdi Gibani, Christopher Chiu, Sigrid C J de Keersmaecker, Dileep Dasyam, Sandra Morel, Jeanne-Marie Devaster, Nicoletta Corti, Ed J Kuijper, Meta Roestenberg, Wiep Klaas Smits
{"title":"如何开发艰难梭状芽孢杆菌控制性人体感染模型。","authors":"Annefleur D O Hensen, Maria J G T Vehreschild, Dale N Gerding, Oleg Krut, Wilbur Chen, Vincent B Young, Saul Tzipori, Philipp Solbach, Malick Mahdi Gibani, Christopher Chiu, Sigrid C J de Keersmaecker, Dileep Dasyam, Sandra Morel, Jeanne-Marie Devaster, Nicoletta Corti, Ed J Kuijper, Meta Roestenberg, Wiep Klaas Smits","doi":"10.1016/j.cmi.2024.08.025","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clostridioides difficile (C. difficile) remains the leading cause of healthcare-associated diarrhoea, posing treatment challenges because of antibiotic resistance and high relapse rates. Faecal microbiota transplantation is a novel treatment strategy to prevent relapses of C. difficile infection (CDI), however, the exact components conferring colonization resistance are unknown, hampering its translation to a medicinal product. The development of novel products independent of antibiotics, which increase colonization resistance or induce protective immune mechanisms is urgently needed.</p><p><strong>Objectives: </strong>To establish a framework for a Controlled Human Infection Model (CHIM) of C. difficile, in which healthy volunteers are exposed to toxigenic C. difficile spores, offering the possibility to test novel approaches and identify microbiota and immunological targets. Whereas experimental exposure to non-toxigenic C. difficile has been done before, a toxigenic C. difficile CHIM faces ethical, scientific, logistical, and biosafety challenges.</p><p><strong>Sources: </strong>Specific challenges in developing a C. difficile CHIM were discussed by a group of international experts during a workshop organized by Inno4Vac, an Innovative Health Initiative-funded consortium.</p><p><strong>Content: </strong>The experts agreed that the main challenges are: developing a clinically relevant CHIM that induces mild to moderate CDI symptoms but not severe CDI, determining the optimal C. difficile inoculum dose, and understanding the timing and duration of antibiotic pretreatment in inducing susceptibility to CDI in healthy volunteers.</p><p><strong>Implications: </strong>Should these challenges be tackled, a C. difficile CHIM will not only provide a way forward for the testing of novel products but also offer a framework for a better understanding of the pathophysiology, pathogenesis, and immunology of C. difficile colonization and infection.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":" ","pages":""},"PeriodicalIF":10.9000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"How to develop a controlled human infection model for Clostridioides difficile.\",\"authors\":\"Annefleur D O Hensen, Maria J G T Vehreschild, Dale N Gerding, Oleg Krut, Wilbur Chen, Vincent B Young, Saul Tzipori, Philipp Solbach, Malick Mahdi Gibani, Christopher Chiu, Sigrid C J de Keersmaecker, Dileep Dasyam, Sandra Morel, Jeanne-Marie Devaster, Nicoletta Corti, Ed J Kuijper, Meta Roestenberg, Wiep Klaas Smits\",\"doi\":\"10.1016/j.cmi.2024.08.025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Clostridioides difficile (C. difficile) remains the leading cause of healthcare-associated diarrhoea, posing treatment challenges because of antibiotic resistance and high relapse rates. Faecal microbiota transplantation is a novel treatment strategy to prevent relapses of C. difficile infection (CDI), however, the exact components conferring colonization resistance are unknown, hampering its translation to a medicinal product. The development of novel products independent of antibiotics, which increase colonization resistance or induce protective immune mechanisms is urgently needed.</p><p><strong>Objectives: </strong>To establish a framework for a Controlled Human Infection Model (CHIM) of C. difficile, in which healthy volunteers are exposed to toxigenic C. difficile spores, offering the possibility to test novel approaches and identify microbiota and immunological targets. Whereas experimental exposure to non-toxigenic C. difficile has been done before, a toxigenic C. difficile CHIM faces ethical, scientific, logistical, and biosafety challenges.</p><p><strong>Sources: </strong>Specific challenges in developing a C. difficile CHIM were discussed by a group of international experts during a workshop organized by Inno4Vac, an Innovative Health Initiative-funded consortium.</p><p><strong>Content: </strong>The experts agreed that the main challenges are: developing a clinically relevant CHIM that induces mild to moderate CDI symptoms but not severe CDI, determining the optimal C. difficile inoculum dose, and understanding the timing and duration of antibiotic pretreatment in inducing susceptibility to CDI in healthy volunteers.</p><p><strong>Implications: </strong>Should these challenges be tackled, a C. difficile CHIM will not only provide a way forward for the testing of novel products but also offer a framework for a better understanding of the pathophysiology, pathogenesis, and immunology of C. difficile colonization and infection.</p>\",\"PeriodicalId\":10444,\"journal\":{\"name\":\"Clinical Microbiology and Infection\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":10.9000,\"publicationDate\":\"2024-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Microbiology and Infection\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cmi.2024.08.025\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Microbiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cmi.2024.08.025","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:艰难梭菌(C. difficile)仍然是医疗相关性腹泻的主要病因,其抗生素耐药性和高复发率给治疗带来了挑战。粪便微生物群移植(FMT)是一种新型治疗策略,可预防艰难梭菌感染(CDI)复发,但产生定植耐药性的确切成分尚不清楚,这阻碍了将其转化为医药产品。我们迫切需要开发出独立于抗生素的新型产品,以提高耐定植性或诱导保护性免疫机制:建立艰难梭菌受控人类感染模型(CHIM)框架,让健康志愿者暴露于毒性艰难梭菌孢子中,为测试新方法、确定微生物群和免疫学靶点提供可能性。虽然以前曾进行过接触非致毒艰难梭菌(NTCD)的实验,但致毒艰难梭菌 CHIM 面临着伦理、科学、后勤和生物安全方面的挑战:在由国际医疗卫生机构(IHI)资助的 Inno4Vac 联合企业组织的一次研讨会上,一组国际专家讨论了开发艰难梭菌 CHIM 所面临的具体挑战:专家们一致认为主要挑战在于:开发一种与临床相关的 CHIM,诱导轻度至中度 CDI 症状,但不诱导重度 CDI;确定最佳艰难梭菌接种剂量;了解抗生素预处理在诱导健康志愿者对 CDI 易感性方面的时机和持续时间:如果能解决这些难题,艰难梭菌CHIM不仅能为新型产品的测试提供前进的方向,还能为更好地了解艰难梭菌定植和感染的病理生理学、发病机理和免疫学提供一个框架。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
How to develop a controlled human infection model for Clostridioides difficile.

Background: Clostridioides difficile (C. difficile) remains the leading cause of healthcare-associated diarrhoea, posing treatment challenges because of antibiotic resistance and high relapse rates. Faecal microbiota transplantation is a novel treatment strategy to prevent relapses of C. difficile infection (CDI), however, the exact components conferring colonization resistance are unknown, hampering its translation to a medicinal product. The development of novel products independent of antibiotics, which increase colonization resistance or induce protective immune mechanisms is urgently needed.

Objectives: To establish a framework for a Controlled Human Infection Model (CHIM) of C. difficile, in which healthy volunteers are exposed to toxigenic C. difficile spores, offering the possibility to test novel approaches and identify microbiota and immunological targets. Whereas experimental exposure to non-toxigenic C. difficile has been done before, a toxigenic C. difficile CHIM faces ethical, scientific, logistical, and biosafety challenges.

Sources: Specific challenges in developing a C. difficile CHIM were discussed by a group of international experts during a workshop organized by Inno4Vac, an Innovative Health Initiative-funded consortium.

Content: The experts agreed that the main challenges are: developing a clinically relevant CHIM that induces mild to moderate CDI symptoms but not severe CDI, determining the optimal C. difficile inoculum dose, and understanding the timing and duration of antibiotic pretreatment in inducing susceptibility to CDI in healthy volunteers.

Implications: Should these challenges be tackled, a C. difficile CHIM will not only provide a way forward for the testing of novel products but also offer a framework for a better understanding of the pathophysiology, pathogenesis, and immunology of C. difficile colonization and infection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
25.30
自引率
2.10%
发文量
441
审稿时长
2-4 weeks
期刊介绍: Clinical Microbiology and Infection (CMI) is a monthly journal published by the European Society of Clinical Microbiology and Infectious Diseases. It focuses on peer-reviewed papers covering basic and applied research in microbiology, infectious diseases, virology, parasitology, immunology, and epidemiology as they relate to therapy and diagnostics.
期刊最新文献
Acute cough in outpatients: what causes it, how long does it last, and how severe is it for different viruses and bacteria? Clinical Microbiology and Infection: how did we do in 2023? Healthcare-seeking behaviour preceding diagnosis of Lyme neuroborreliosis: population-based nationwide matched nested case-control study. COVID-19 surge during summer 2024: the phantom menace? Impact of susceptible, increased exposure, a new definition of the former intermediate susceptibility category, introduced by the European Committee for Antimicrobial Susceptibility Testing on antimicrobial susceptibility testing evaluation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1